Helix BioPharma Corp.

TSX:HBP.TO

0.9 (CAD) • At close October 29, 2024
Bedrijfsnaam Helix BioPharma Corp.
Symbool HBP.TO
Munteenheid CAD
Prijs 0.9
Beurswaarde 44,119,350
Dividendpercentage 0%
52-weken bereik 0.8 - 1.35
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jacek Antas
Website https://www.helixbiopharma.com

An error occurred while fetching data.

Over Helix BioPharma Corp.

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and

Vergelijkbare Aandelen

Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc.

EPRX.TO

3.5 CAD

Antibe Therapeutics Inc. logo

Antibe Therapeutics Inc.

ATE.TO

0.295 CAD

Financiële Gegevens

Cijfers zijn in miljoenen (CAD)

Cijfers zijn in miljoenen (CAD)